 |
Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter. |
After Appeals Court Victory, Myriad Looks to Debunk 'Misconceptions' on How it Enforces DNA Patents
August 22, 2012
After Appeals Court Victory, Myriad Looks to Debunk 'Misconceptions' on How it Enforces DNA Patents
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Will Insurers Cover $700 for Myriad's Large Rearrangement Test Plus $3K for BRACAnalysis?
August 15, 2012 / Pharmacogenomics Reporter - Federal Circuit Judges Considered USPTO Policy, Industry Impact in Ruling on Myriad's Gene Patents
August 22, 2012 / Pharmacogenomics Reporter - 'Isolated DNA' Definition May Be Biggest Barrier to Summary Judgment at Anti-Gene Patenting Hearing
February 3, 2010 / Pharmacogenomics Reporter - SCOTUS Justices Struggle to Draw Line between Isolated DNA, cDNA in Gene Patent Hearing
April 17, 2013 / Pharmacogenomics Reporter - Hearing on Second-Opinion Genetic Testing Highlights Risks of Athena's Exclusive Licensing Practices
January 16, 2013 / Pharmacogenomics Reporter